<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVES: To report the successful and uncomplicated use of systemic thrombolysis for massive <z:hpo ids='HP_0002204'>pulmonary embolism</z:hpo> in a patient with a known <z:hpo ids='HP_0002408'>cerebral arteriovenous malformation</z:hpo> and to suggest that the presence of an unruptured <z:hpo ids='HP_0100026'>arteriovenous malformation</z:hpo> or <z:hpo ids='HP_0002617'>aneurysm</z:hpo> should not be considered an absolute contraindication to systemic thrombolysis </plain></SENT>
<SENT sid="1" pm="."><plain>DESIGN: Case report </plain></SENT>
<SENT sid="2" pm="."><plain>SETTING: A 16-bed adult neurologic/medical intensive care unit in a university hospital </plain></SENT>
<SENT sid="3" pm="."><plain>PATIENTS: A patient developed a massive <z:hpo ids='HP_0002204'>pulmonary embolism</z:hpo> the morning after elective cerebral embolization of a large unruptured <z:hpo ids='HP_0002408'>cerebral arteriovenous malformation</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>INTERVENTION: Radial artery catheterization, arterial blood gas measurements, mechanical ventilation, vasopressors, pulmonary perfusion scan, echocardiogram, head computed tomography, <z:chebi fb="5" ids="28304">heparin</z:chebi> therapy, and systemic recombinant tissue plasminogen activator therapy </plain></SENT>
<SENT sid="5" pm="."><plain>MEASUREMENT AND MAIN RESULTS: The patient required emergent mechanical ventilation and vasopressor support for respiratory and hemodynamic failure </plain></SENT>
<SENT sid="6" pm="."><plain>Echocardiogram showed <z:hpo ids='HP_0011009'>acute</z:hpo> right <z:hpo ids='HP_0001635'>heart failure</z:hpo>, and pulmonary perfusion scan demonstrated massive <z:hpo ids='HP_0002204'>pulmonary embolism</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>Despite intravenous <z:chebi fb="5" ids="28304">heparin</z:chebi> therapy, the patient had worsening <z:hpo ids='HP_0002615'>hypotension</z:hpo> and <z:hpo ids='HP_0001941'>acidosis</z:hpo> and we therefore treated with recombinant tissue plasminogen activator </plain></SENT>
<SENT sid="8" pm="."><plain>Within the next day the patient was weaned from vasopressor support and extubated </plain></SENT>
<SENT sid="9" pm="."><plain>Neurologic examination remained <z:mpath ids='MPATH_458'>normal</z:mpath>, and follow-up head computed tomography revealed no evidence of <z:hpo ids='HP_0002170'>intracranial hemorrhage</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSION: Known <z:hpo ids='HP_0100026'>arteriovenous malformations</z:hpo> or <z:hpo ids='HP_0002617'>aneurysms</z:hpo> are considered a contraindication to thrombolysis, although the true risk of thrombolysis-precipitated <z:hpo ids='HP_0002170'>intracranial hemorrhage</z:hpo> is unknown </plain></SENT>
<SENT sid="11" pm="."><plain>We believe that this risk is low in the setting of a previously unruptured <z:hpo ids='HP_0100026'>arteriovenous malformation</z:hpo> or <z:hpo ids='HP_0002617'>aneurysm</z:hpo> </plain></SENT>
<SENT sid="12" pm="."><plain>The decision to use systemic thrombolysis in a patient with a known vascular malformation should be individualized </plain></SENT>
</text></document>